Hyperlipidemia is a potent risk factor for atherosclerosis and coronary heart disease (CHD) and is present in a substantial proportion of young adults. According to data from the National Health and Nutrition Examination Survey (NHANES), between 11.7% of adults aged 20-39 and 41.2% of adults aged 40-64 had elevated low-density lipoprotein cholesterol (LDL-C) levels, but only 10.6% of adults aged 20-39 and 47.7% of adults age 40-64 with hyperlipidemia were on treatment. 1 The newly released American Heart Association (AHA)/American College of Cardiology (ACC) guidelines for treatment of blood cholesterol for the prevention of cardiovascular disease (CVD) recommend statin therapy for all adults with prevalent CVD, LDL-C 190 mg/dl, diabetes, or 10-year risk of atherosclerotic CVD 7.5%, as assessed by the new Pooled Cohort Equations. 2 Although CHD events such as myocardial infarction present suddenly, the advanced extensive complex intramural lesions that lead to plaque rupture develop over decades. Since the natural history of atherosclerosis is prolonged, the risk of clinical events rises exponentially late in life. As a result, the new cholesterol guidelines led to a high number of older adults aged 60 years to be recommended for statin therapy, with relatively fewer younger adults meeting statin recommendation tresholds. 1 Studies on adults with familial hypercholesterolemia have shown CVD risk is increased early among those with very high LDL-C levels. 3 Similarly, adults with extremely low LDL-C levels conferred by genetic polymorphisms have significantly lower than average risk of CVD. 4, 5 However, the association between prolonged exposure to mild to moderately elevated lipid levels in young adulthood on an individual's subsequent risk of CHD has not previously been well described. 6 Therefore, we used the Framingham Offspring Study to address the impact of duration of hyperlipidemia in young adulthood (ages 35 to 55) and future risk of CHD beyond age 55 years.
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Methods

Study Design and Sample
Our study examined data on 5124 individuals from the Offspring Cohort of the Framingham Heart Study recruited between 1971 and 1975. 7 In order to identify participants with sufficient observation time to evaluate both the number of years of exposure to hyperlipidemia, as well as the person's future risk of CHD, participants were eligible for inclusion in this analysis if: 1) they had attended Offspring Cohort examination 4 (1987-1991) , 5 (1991-1995) , or 6 (1995-1998); 2) were between the ages of 53 and 57 years; and 3) were free of CVD (defined as myocardial infarction, angina, coronary insufficiency, transient ischemic attack, stroke, coronary heart disease death, cardiovascular death, intermittent claudication, or heart failure 8 ) at the time of eligibility assessment. Of exams 4, 5, and 6, the exam closest to age 55 was used as the "baseline" visit. Data from prior exams were used to evaluate the number of years of hyperlipidemia attained by the baseline age. This resulted in a sample of 1478 adults free of CVD at the baseline examination, who were approximately 55 years of age. Participants were then prospectively followed for up to 20 years for the development of CHD (myocardial infarction, angina, coronary insufficiency, coronary heart disease death) events. Median followup was 15 years.
Outcomes and Exposures
The primary factor of interest was the number of years of exposure to hyperlipidemia in the 20 years prior to the baseline visit at age 55 (e.g., number of years of elevated non-high-density lipoprotein cholesterol [HDL-C] between ages 35 and 55). Consistent with the lipid measures used in the newest Pooled Cohort Equations, hyperlipidemia in our primary analysis was defined based on non-HDL-C, with levels 160 mg/dL considered elevated. This level is equivalent to heart disease death, cardiovascular death, intermittent claudication, or heart failu ur r re 8 8 8 ) ) ) a at at t t the he he t t tim im ime of eligibility assessment. Of exams 4, 5, and 6, the exam closest to age 55 was used as the the time interval between study visits, we assumed that the date of development was midway between the two exams. For individuals with fewer than 20 years of data prior to baseline, we conservatively assumed that the participant was free of hyperlipidemia for the time period without data. For participants with missing data at any follow-up exam, the value from the prior exam was carried forward.
In sensitivity analyses we also examined prior elevation of non-HDL-C as a continuous variable. Each person's average non-HDL-C over the preceding 20 years was calculated,
weighted by the number of years between exams. In addition, LDL-C, rather than non-HDL-C was evaluated using number of years with LDL-C 130 mg/dL. Because the Friedewald equation was used to calculate LDL-C, adults with triglycerides over 400 mg/dL at any time were excluded from the LDL-C analysis.
Statistical Analysis
First, using the number of years of hyperlipidemia by age 55, adults were stratified into three groups: 1) those without hyperlipidemia by age 55; 2) those with 1-10 years of hyperlipidemia; and 3) those with 11-20 years of hyperlipidemia. Kaplan-Meier survival curves were generated to evaluate the risk of CHD over the subsequent years, and the log-rank test was used to test the overall survival experience.
Cox proportional hazards regression models were employed to evaluate the relative risk of increasing the number of years with hyperlipidemia on the onset of CHD events by evaluating the association between number of years of exposure to hyperlipidemia at age 55 as a continuous As secondary analyses, we repeated our primary analysis of association between years of exposure to non-HDL-C 160 mg/dL in our sample of young adults who would not be specifically recommended for statin therapy under the 2013 AHA/ACC guidelines. This excluded adults with 10-year CVD risk 7.5%, diabetes with LDL-C 70 mg/dL, or LDL-C 190 mg/dL.
Statistical An An nal al alys ys ysis is is
Next, we assessed the proportion of adults who would have been recommended for statin therapy at age 40 and age 50 under current guidelines based on diabetes status, LDL-C, and 10-year CVD risk, stratified by years of exposure to hyperlipidemia (zero, 1-10, and 11-20 years of hyperlipidemia). We considered both the 7.5% and the 5% risk thresholds to determine treatment eligibility per the new guidelines. This analysis was performed to determine the extent to which individuals with prolonged hyperlipidemia would have been identified as treatment baseline and over the follow-up period in a time-dependent fashion. Hazard ratio os s fo fo for th th he e e association between duration of hyperlipidemia and future CHD risk are presented per 10-year n ncr cr rea ea eas se se.
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in the analysis that evaluated statin recommendations.
In sensitivity analysis, we investigated the robustness of our results to the choice of lipid parameter and choice of threshold. First, the association between years of exposure to LDL-C 130 mg/dL and future CHD was evaluated using multivariable Cox proportional hazards modeling. Second, to determine whether the results depend on the 160 mg/dL non-HDL-C threshold, the association between the weighted average non-HDL-C over the prior 20 years and future risk of CHD was evaluated using restricted cubic splines. Inflection points in the graph, The analysis was approved by the Duke University Institutional Review Board. All
Framingham Offspring cohort participants gave informed consent for participation. Statistical analysis was performed using SAS version 9.3.
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Results
Study Population
Characteristics of the study sample at baseline are presented in Table 1 . A total of 124 individuals in the cohort developed CVD prior to age 55 and were not included in our sample.
The final sample included 1478 adults free of CVD at baseline with 0-20 years of hyperlipidemia. Of these, 512 adults did not have hyperlipidemia, 389 adults had 1-10 years of hyperlipidemia, and 577 adults had 11-20 years of hyperlipidemia exposure by baseline age.
Individuals with hyperlipidemia at baseline were more likely to be diabetic, male, and smokers, and had higher SBP, body mass index, total cholesterol levels, and lower HDL-C levels than those without hyperlipidemia. Only 85 patients overall (5.8%) were on lipid-lowering treatment at the baseline visit. hyperlipidemia, and 4.4% (2.9-6.6%) for those without hyperlipidemia at baseline.
Years of Hyperlipidemia and Risk of CHD
The unadjusted risk of CHD doubled for every ten years of exposure to hyperlipidemia ( 
Statin Recommendations Under Current Guidelines
The number of participants who would be specifically targeted for statin therapy according to the statin benefit groups as identified by the new guidelines was calculated ( When we restricted our analyses to those adults not recommended for statin therapy at age 55 (i.e., 10-year CVD risk below 7.5%, LDL-C <190 mg/dL, and no diabetes with LDL-C 70 mg/dL; n=971), the association between hyperlipidemia and risk of CHD was preserved;
adults with both 1-10 and 11-20 years of hyperlipidemia at baseline had significantly higher rates of CHD compared with adults without hyperlipidemia (Figure 2, p<0.001 ). In tatin benefit groups as identified by the new guidelines was calculated ( Table 3 3) ) ). O O Of f 57 57 577 7 7 ad ad adul ults with 11-20 years of hyperlipidemia at the index age of 55, 87 (15.1%) participants would have me met t t cr cr rit it iter eria ia ia f f fo o or s sta ta tati ti t n therapy at age 40, and 201 1 ( ( (34 4 4.8%) would h h hav a a e me me met t criteria at age 50.
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Sensitivity Analyses
Using an LDL-C level of 130 mg/dL rather than non-HDL-C 160 mg/dL as the primary exposure yielded similar results (appendix table 1 years was as sso so oci ci c at at ted ed ed w w wit it i h a a a 33 33 3 % % % in in i cr cr c ea a ase se se i in n n fu fu futu tu t re re re C C CHD HD D r r ris is isk k k (H (H (HR R R pe pe per r r 10 10 10 m m mg/ g/dL dL dL i i inc nc ncre re r ase 1.33, fold increased rate of CHD at follow-up. Importantly, not only does prevalent hyperlipidemia increase future risk of CHD, but the length of exposure to hyperlipidemia in the fourth and fifth decades of life affects future CHD risk in a dose-responsive manner as the association between exposure to hyperlipidemia in young adulthood and future CHD remained highly significant even after adjustment for non-HDL-C at age 55. This association was preserved in individuals without direct recommendations for statin therapy under the current guidelines. These findings are aligned with the biological understanding of atherosclerosis as a progressive disease due to ongoing vessel injury over time-a substantial part of which is caused by elevated cholesterol levels. 6 In addition to the 10-year risk, which was calculated using the Pooled Cohort Equations, the current AHA/ACC cholesterol guideline recommends when making treatment decisions to consider family history, C-reactive protein, coronary artery calcium, ankle brachial index, and lifetime CVD risk. Our data suggests that sustained moderate elevation of lipid levels also confers a substantial risk of future events. Given the potent association between duration of exposure to hyperlipidemia by mid-adulthood and future CHD risk, clinicians should also consider lifestyle intervention or even treatment for adults with prolonged prior exposure to hyperlipidemia. Randomized controlled trial evidence support the clinical benefit of statin therapy for primary prevention in adults in this age group, with a number of primary prevention trials demonstrating that statins initiated in midlife significantly reduce future clinical events.
9-11
While the new guidelines identify those patients with a very high lipid level on a single measurement (LDL-C 190 mg/dL) as candidates for statin therapy, they do not further differentiate risk in others based on lipoprotein levels. Under current guidelines, only one in six adults in this cohort with prolonged duration of exposure to hyperlipidemia would have been
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Limitations and Strengths
Our analysis has several limitations. First, we only included adults aged 53-57 who were free of CVD; therefore, the point estimates cannot be extrapolated outside of this age range.
Nevertheless, we believe that this analysis demonstrates the long-term impact of hyperlipidemia in young adulthood. Second, our analysis defined hyperlipidemia using a non-HDL-C cutoff of 160 mg/dL, which is consistent with how the prior Adult Treatment Panel (ATP) III guidelines defined elevated cholesterol; given that the risk of CHD events expands with increasing levels of non-HDL-C, the use of this or any cut-point may have falsely dichotomized a continuous relationship. However, using a continuous approach which averaged non-HDL-C over the preceding 20 years yielded similar results, showing that the risk associated with exposure to nono reduce cardiovascular disease later in life. This analysis also highlights the fact ct t t tha ha h t t t ri ri risk sk sk prediction models focused on a 10-year horizon may underestimate the contribution of prolonged ex xpo po posu su sure re t t to o o ch ch c ro oni ni nic c disease, and the need to cont nt ntin inu ue to evaluate e ho h h w w to to to b best incorporate 30-year or l li if ifetime risk k e est tim imat a ates es s i i in nt nto o o c c cur urre re ren nt nt p p pre even n nti ion gu gu guide el eli in nes es s. 1 12, 12, 13 13 13
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Conclusions
We conclude that the exposure to hyperlipidemia in the fourth and fifth decades of life is associated with a substantially increased risk of CHD in a dose-responsive fashion, even among adults otherwise predicted to have low risk of CVD. Our findings suggest that adults with longstanding moderate elevations in non-HDL-C should be added to those already identified by the current guidelines as candidates for an informed patient-physician discussion about appropriate lipid management strategies to reduce future risk of heart disease.
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